SCHEMBL12212

SCHEMBL12212

O=C1CCC(C(=O)O)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12219 1.00
SCHEMBL12268 1.00
Hydrochloric Acid SCHEMBL1372283 0.98 CA1 (0.43)
Iodide SCHEMBL10698321 0.98 CA1 (0.43)
Hydrochloric Acid SCHEMBL1372279 0.98 CA1 (0.43)
SCHEMBL9846779 0.86 CA1 (0.37)
SCHEMBL18302606 0.86 CA1 (0.37)
SCHEMBL5884221 0.85 LMNA (0.41)
SCHEMBL14249431 0.85 POLB (0.39)
SCHEMBL27920507 0.83 CA1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1079 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12551465-B2 Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition CELLTRION INC. (KR) 2026-02-17 US claimed
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-115297858-B Pharmaceutical composition for treating hypertrophic cardiomyopathy and treatment method using the same 赛特瑞恩股份有限公司 2024-08-13 CN claimed
US-11999741-B2 Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one CARDURION PHARMACEUTICALS, INC. (US) 2024-06-04 US claimed
CN-117105931-A Method for preparing pyridopyrimidine compounds and intermediate thereof 上海翰森生物医药科技有限公司 2023-11-24 CN claimed
US-20230190708-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION CELLTRION, INC. (KR) 2023-06-22 US claimed
US-20230122169-A1 NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE CELLTRION, INC. (KR) 2023-04-20 US claimed
EP-4140482-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION Celltrion, Inc. (KR) 2023-03-01 EP claimed
EP-3118211-B1 AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA-AND/OR DNA-CONTAINING VIRUSES AND CONCOMITANT DISEASES OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) 2022-10-12 EP claimed
EP-0640074-B1 SALTS OF A QUINOLONE-CARBOXYLIC ACID CHEIL FOODS & CHEM (KR) 1998-11-11 EP claimed
EP-0713495-A4 METHODS OF ENHANCING BIOACTIVITY OF CHEMOKINES SMITHKLINE BEECHAM CORP (US) 1998-06-03 EP claimed
JP-H08511167-A 1996-11-26 JP claimed
EP-0713495-A1 METHODS OF ENHANCING BIOACTIVITY OF CHEMOKINES SMITHKLINE BEECHAM CORPORATION (US) 1996-05-29 EP claimed
US-5484785-A BACTERICIDES CHEIL FOODS & CHEMICALS, INC. (KR) 1996-01-16 US claimed
EP-0640074-A1 NOVEL SALTS OF A QUINOLONE-CARBOXYLIC ACID CHEIL FOODS &amp; CHEMICALS, INC. (KR) 1995-03-01 EP claimed
WO-1995005684-A1 USE OF STABLE FORM OF LiMnO2 AS CATHODE IN LITHIUM CELL NATIONAL RESEARCH COUNCIL OF CANADA (CA) 1995-02-23 WO claimed
WO-1994029341-A1 METHODS OF ENHANCING BIOACTIVITY OF CHEMOKINES SMITHKLINE BEECHAM CORPORATION (US) 1994-12-22 WO claimed
WO-1993014068-A1 NOVEL SALTS OF A QUINOLONE-CARBOXYLIC ACID CHEIL FOODS & CHEMICALS, INC. (KR) 1993-07-22 WO claimed
EP-0285884-A2 Process to produce 2', 3'-Dideoxynucleosides Bristol-Myers Squibb Company (US) 1988-10-12 EP claimed